A novel FGFR3 splice variant preferentially expressed in african american prostate cancer drives aggressive phenotypes and docetaxel resistance
Document Type
Journal Article
Publication Date
10-1-2019
Journal
Molecular Cancer Research
Volume
17
Issue
10
DOI
10.1158/1541-7786.MCR-19-0415
Abstract
© 2019 American Association for Cancer Research. Alternative splicing (AS) has been shown to participate in prostate cancer development and progression; however, a link between AS and prostate cancer health disparities has been largely unexplored. Here we report on the cloning of a novel splice variant of FGFR3 that is preferentially expressed in African American (AA) prostate cancer. This novel variant (FGFR3-S) omits exon 14, comprising 123 nucleotides that encode the activation loop in the intracellular split kinase domain. Ectopic overexpression of FGFR3-S in European American (EA) prostate cancer cell lines (PC-3 and LNCaP) led to enhanced receptor autophosphorylation and increased activation of the downstream signaling effectors AKT, STAT3, and ribosomal S6 compared with FGFR3-L (retains exon 14). The increased oncogenic signaling imparted by FGFR3-S was associated with a substantial gain in proliferative and antiapoptotic activities, as well as a modest but significant gain in cell motility. Moreover, the FGFR3-S-conferred proliferative and motility gains were highly resistant to the pan-FGFR smallmolecule inhibitor dovitinib and the antiapoptotic gain was insensitive to the cytotoxic drug docetaxel, which stands in marked contrast with dovitinib- and docetaxel-sensitive FGFR3-L. In an in vivo xenograft model, mice injected with PC-3 cells overexpressing FGFR3-S exhibited significantly increased tumor growth and resistance to dovitinib treatment compared with cells overexpressing FGFR3-L. In agreement with our in vitro and in vivo findings, a high FGFR3-S/FGFR3-L expression ratio in prostate cancer specimens was associated with poor patient prognosis.
APA Citation
Olender, J., Wang, B., Ching, T., Garmire, L., Garofano, K., Ji, Y., Knox, T., Latham, P., Nguyen, K., Rhim, J., & Lee, N. (2019). A novel FGFR3 splice variant preferentially expressed in african american prostate cancer drives aggressive phenotypes and docetaxel resistance. Molecular Cancer Research, 17 (10). http://dx.doi.org/10.1158/1541-7786.MCR-19-0415